PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12740386-4 2003 The immunosuppressant FK506 failed to inhibit p70S6K activation, but was able to rescue the rapamycin-induced downshift, pointing to a role for the mammalian target of rapamycin (mTOR) kinase. Tacrolimus 22-27 mechanistic target of rapamycin kinase Homo sapiens 148-177 12740386-4 2003 The immunosuppressant FK506 failed to inhibit p70S6K activation, but was able to rescue the rapamycin-induced downshift, pointing to a role for the mammalian target of rapamycin (mTOR) kinase. Tacrolimus 22-27 mechanistic target of rapamycin kinase Homo sapiens 179-183 11792863-9 2002 The inhibition by rapamycin was blocked by FK506, which competitively inhibits those effects of rapamycin that are mediated by inhibition of mTOR. Tacrolimus 43-48 mechanistic target of rapamycin kinase Homo sapiens 141-145 34046945-7 2021 After mTOR initiation, 50% of patients were reduced or weaned off tacrolimus and 13.7% off prednisone. Tacrolimus 66-76 mechanistic target of rapamycin kinase Homo sapiens 6-10 34847842-11 2021 The officially accepted mTOR inhibitors that have undergone clinical testing are sirolimus, everolimus, temsirolimus, and tacrolimus. Tacrolimus 122-132 mechanistic target of rapamycin kinase Homo sapiens 24-28 33830489-3 2021 We report three cases of cobicistat-tacrolimus co-administration, two of which also include the co-administration of mTOR inhibitors, in HIV-positive patients undergoing SOT (2 kidney and 1 liver recipient). Tacrolimus 36-46 mechanistic target of rapamycin kinase Homo sapiens 117-121 10775131-5 2000 Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked flow-induced pp70(S6k) activation; FK-506, a rapamycin analog with minimal mTOR inhibitory activity, and PD-98059, an inhibitor of the flow-sensitive mitogen-activated protein kinase pathway, had no effect. Tacrolimus 171-177 mechanistic target of rapamycin kinase Homo sapiens 31-60 10775131-5 2000 Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked flow-induced pp70(S6k) activation; FK-506, a rapamycin analog with minimal mTOR inhibitory activity, and PD-98059, an inhibitor of the flow-sensitive mitogen-activated protein kinase pathway, had no effect. Tacrolimus 171-177 mechanistic target of rapamycin kinase Homo sapiens 62-66 34793770-2 2022 The mammalian target of rapamycin (mTOR) inhibitor, everolimus, is an immunosuppressant used together with tacrolimus. Tacrolimus 107-117 mechanistic target of rapamycin kinase Homo sapiens 4-33 34793770-2 2022 The mammalian target of rapamycin (mTOR) inhibitor, everolimus, is an immunosuppressant used together with tacrolimus. Tacrolimus 107-117 mechanistic target of rapamycin kinase Homo sapiens 35-39 33145270-0 2020 Differential expression of genes related to calcineurin and mTOR signaling and regulatory miRNAs in peripheral blood from kidney recipients under tacrolimus-based therapy. Tacrolimus 146-156 mechanistic target of rapamycin kinase Homo sapiens 60-64 32541562-5 2021 As we enter the fourth decade of tacrolimus use, newer studies utilizing of novel combinations (as with the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and T-cell co-stimulation blockade with belatacept) offer potential for enhanced benefits. Tacrolimus 33-43 mechanistic target of rapamycin kinase Homo sapiens 108-137 33431785-0 2021 Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus. Tacrolimus 178-188 mechanistic target of rapamycin kinase Homo sapiens 51-80 32956634-2 2020 Among the seven mTOR inhibitors evaluated, tacrolimus (TAC) showed significant dose- and time-dependent killing of cultured protoscoleces and cysts in vitro. Tacrolimus 43-53 mechanistic target of rapamycin kinase Homo sapiens 16-20 32956634-2 2020 Among the seven mTOR inhibitors evaluated, tacrolimus (TAC) showed significant dose- and time-dependent killing of cultured protoscoleces and cysts in vitro. Tacrolimus 55-58 mechanistic target of rapamycin kinase Homo sapiens 16-20 33145270-10 2020 Conclusions: The expression of PPP3CA, MTOR and miR-99a in the peripheral blood of renal recipients is influenced by tacrolimus-based therapy and by PPP3CA and MTOR variants. Tacrolimus 117-127 mechanistic target of rapamycin kinase Homo sapiens 39-43 33145270-10 2020 Conclusions: The expression of PPP3CA, MTOR and miR-99a in the peripheral blood of renal recipients is influenced by tacrolimus-based therapy and by PPP3CA and MTOR variants. Tacrolimus 117-127 mechanistic target of rapamycin kinase Homo sapiens 160-164 25491391-7 2014 The current study will test the hypothesis that MSC treatment, in combination with the mTOR inhibitor everolimus, facilitates tacrolimus withdrawal, reduces fibrosis and decreases the incidence of opportunistic infections compared to standard tacrolimus dose. Tacrolimus 126-136 mechanistic target of rapamycin kinase Homo sapiens 87-91 32006551-5 2020 Transcription assays of calcineurin (CaN)- and mTOR (mammalian target of rapamycin)-downstream target genes confirm that BbFKBP12 is the target of both FK506 and rapamycin, associated with CaN- and mTOR-signal pathways in B. bassiana. Tacrolimus 152-157 mechanistic target of rapamycin kinase Homo sapiens 47-51 32006551-5 2020 Transcription assays of calcineurin (CaN)- and mTOR (mammalian target of rapamycin)-downstream target genes confirm that BbFKBP12 is the target of both FK506 and rapamycin, associated with CaN- and mTOR-signal pathways in B. bassiana. Tacrolimus 152-157 mechanistic target of rapamycin kinase Homo sapiens 53-82 32006551-5 2020 Transcription assays of calcineurin (CaN)- and mTOR (mammalian target of rapamycin)-downstream target genes confirm that BbFKBP12 is the target of both FK506 and rapamycin, associated with CaN- and mTOR-signal pathways in B. bassiana. Tacrolimus 152-157 mechanistic target of rapamycin kinase Homo sapiens 198-202 31271885-2 2019 Sirolimus is a mammalian target of rapamycin inhibitor that has proven effective in GVHD prophylaxis in combination with a calcineurin inhibitor, such as tacrolimus. Tacrolimus 154-164 mechanistic target of rapamycin kinase Homo sapiens 15-44 31385180-1 2019 PURPOSE: In large observational studies of adult kidney transplant recipients (KTRs) where older adults (65 years old and older) were not well represented, the mammalian target of rapamycin inhibitors (mTOR inhibitors) has poorer outcomes than the standard tacrolimus-mycophenolate-steroids (TAC-MPA-S) regimen. Tacrolimus 257-267 mechanistic target of rapamycin kinase Homo sapiens 202-206 30532015-1 2019 Rapamycin and FK506 are macrocyclic natural products with an extraordinary mode of action, in which they form binary complexes with FK506-binding protein (FKBP) through a shared FKBP-binding domain before forming ternary complexes with their respective targets, mechanistic target of rapamycin (mTOR) and calcineurin, respectively. Tacrolimus 14-19 mechanistic target of rapamycin kinase Homo sapiens 295-299 29757021-7 2018 Other studies report that Advagraf -treated patients receiving a mTOR-inhibitor agent (sirolimus or everolimus) instead of MMF: this was associated with good allograft outcome, and might also prevent late-onset cytomegalovirus infection. Tacrolimus 26-34 mechanistic target of rapamycin kinase Homo sapiens 65-69 28633129-4 2017 On the concentration level of 2-5mug/ml tacrolimus plus 10ng/ml PDGF-BB, combination of drugs could effectively promote ECs proliferation and migration, and meanwhile inhibit VSMCs proliferation and migration, and the inhibition of p-mTOR"s expression within VSMCs played an important role in this differentiated effect. Tacrolimus 40-50 mechanistic target of rapamycin kinase Homo sapiens 234-238 32732848-9 2020 CONCLUSIONS: This single-center retrospective cohort analysis suggests that in hypersensitized kidney transplant recipients receiving tacrolimus-based immunosuppressive therapy similar clinical outcomes may be obtained using mTOR inhibitors compared to mycophenolate. Tacrolimus 134-144 mechanistic target of rapamycin kinase Homo sapiens 225-229 31413313-4 2020 The association of tacrolimus and mTOR inhibitor is supported by pre-clinical data and has been used as GVHD prophylaxis. Tacrolimus 19-29 mechanistic target of rapamycin kinase Homo sapiens 34-38 31447189-2 2019 The aim of this study is to analyze the role of mTOR inhibitor add-on in tacrolimus-based kidney transplant recipients. Tacrolimus 73-83 mechanistic target of rapamycin kinase Homo sapiens 48-52 31447189-11 2019 CONCLUSIONS: In our preliminary result, mTOR inhibitor add-on in patients with tacrolimus-based regimen revealed less post-KT UC occurrence. Tacrolimus 79-89 mechanistic target of rapamycin kinase Homo sapiens 40-44 29676018-0 2018 Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia. Tacrolimus 16-26 mechanistic target of rapamycin kinase Homo sapiens 63-67 29676018-0 2018 Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia. Tacrolimus 52-62 mechanistic target of rapamycin kinase Homo sapiens 63-67 29676018-1 2018 BACKGROUND: We sought to determine whether conversion from tacrolimus/mycophenolate mofetil (TAC-MMF) into tacrolimus/mTOR inhibitor (TAC-mTOR) immunosuppression would reduce the incidences of BK and CMV viremia after kidney/pancreas (KP) transplantation. Tacrolimus 107-117 mechanistic target of rapamycin kinase Homo sapiens 138-142 29676018-2 2018 METHODS: In this single-center review, the TAC-mTOR cohort (n = 39) was converted at 1 month post-transplant to an mTOR inhibitor and reduced-dose tacrolimus. Tacrolimus 147-157 mechanistic target of rapamycin kinase Homo sapiens 47-51 26613512-9 2016 Moreover, we showed a significant decrease in activation of mTOR Complex 1 downstream targets after treatment with everolimus that was attenuated when combined with tacrolimus, but not with cyclosporin A. Tacrolimus 165-175 mechanistic target of rapamycin kinase Homo sapiens 60-64 24861504-2 2014 This review focuses on the pharmacokinetic interactions and exposure-response relationships of mTOR inhibitors and tacrolimus (TAC), the most widely used CNI. Tacrolimus 115-125 mechanistic target of rapamycin kinase Homo sapiens 95-99 21182472-4 2010 Of note, rapamycin and FK506 bind to FKBP12, and the resulting complexes interfere with distinct intracellular signaling pathways driven, respectively, by the mammalian target of rapamycin and calcineurin phosphatase. Tacrolimus 23-28 mechanistic target of rapamycin kinase Homo sapiens 159-188 23696253-1 2013 The mammalian target of rapamycin inhibitor everolimus (Zortress , Certican ) was recently approved in the USA and a number of EU countries for use in combination with a reduced dosage of tacrolimus and corticosteroids for the prophylaxis of organ rejection in adult liver transplant recipients. Tacrolimus 188-198 mechanistic target of rapamycin kinase Homo sapiens 4-33 23577651-1 2013 The use of the mammal target of rapamycin (mTOR) inhibitors has been consolidated as the therapy of election for preventing graft rejection in kidney transplant patients, despite their immunosuppressive activity is less strong than anti-calcineurin agents like tacrolimus and cyclosporine A. Tacrolimus 261-271 mechanistic target of rapamycin kinase Homo sapiens 43-47 22875481-6 2013 RESULTS: Chronic microinjection of CsA or FK506 into mPFC increased depressive-like behaviors and decreased mTOR activity, but acute CsA or FK506 had no effects on both behavioral phenotype and mTOR activity. Tacrolimus 42-47 mechanistic target of rapamycin kinase Homo sapiens 108-112 22875481-7 2013 Furthermore, activation of mTOR by NMDA reversed the depressive-like behavior induced by chronic CsA or FK506 administration. Tacrolimus 104-109 mechanistic target of rapamycin kinase Homo sapiens 27-31 23839048-5 2013 Recent studies have also shown that FK506-binding proteins can modulate Akt-mTOR signaling in the absence of rapamycin. Tacrolimus 36-41 mechanistic target of rapamycin kinase Homo sapiens 76-80 19715866-1 2009 BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants which have the advantages, with respect to calcineurin inhibitors (CNI: cyclosporine or tacrolimus), of no nephrotoxicity and inhibition of cell proliferation. Tacrolimus 184-194 mechanistic target of rapamycin kinase Homo sapiens 12-41 20304212-1 2010 BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants, which have the advantages, with respect to calcineurin inhibitors (CNI; cyclosporine or tacrolimus), of no nephrotoxicity but inhibition of cell proliferation. Tacrolimus 185-195 mechanistic target of rapamycin kinase Homo sapiens 12-41 20304212-1 2010 BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants, which have the advantages, with respect to calcineurin inhibitors (CNI; cyclosporine or tacrolimus), of no nephrotoxicity but inhibition of cell proliferation. Tacrolimus 185-195 mechanistic target of rapamycin kinase Homo sapiens 43-47 19715866-1 2009 BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants which have the advantages, with respect to calcineurin inhibitors (CNI: cyclosporine or tacrolimus), of no nephrotoxicity and inhibition of cell proliferation. Tacrolimus 184-194 mechanistic target of rapamycin kinase Homo sapiens 43-47 19081378-1 2008 FK506-binding protein 12 (FKBP12) binds the immunosuppressant drugs FK506 and rapamycin and regulates several signaling pathways, including mammalian target of rapamycin (mTOR) signaling. Tacrolimus 0-5 mechanistic target of rapamycin kinase Homo sapiens 140-169 19081378-1 2008 FK506-binding protein 12 (FKBP12) binds the immunosuppressant drugs FK506 and rapamycin and regulates several signaling pathways, including mammalian target of rapamycin (mTOR) signaling. Tacrolimus 0-5 mechanistic target of rapamycin kinase Homo sapiens 171-175 17645716-1 2007 The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients. Tacrolimus 214-224 mechanistic target of rapamycin kinase Homo sapiens 4-8 17645716-1 2007 The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients. Tacrolimus 214-224 mechanistic target of rapamycin kinase Homo sapiens 10-39 17038582-4 2007 Here, we show that treatment of T cells with cyclosporin A, FK506, and dexamethasone, which are known to inhibit calcineurin and NF-kappaB, respectively, but not rapamycin, the inhibitor of mammalian target of rapamycin, selectively prevented TCR/CD3 relocalization into the IS, while relocalization of adhesion and cytoskeletal proteins as well as T cell/APC conjugate formation remained unaltered. Tacrolimus 60-65 mechanistic target of rapamycin kinase Homo sapiens 190-219 17175265-12 2006 Our discovery of IRI-induced up-regulation of genes associated with calcineurin and mTOR pathways are consistent with clinical observations that FK506 and Rapamycin can alter the course of DGF. Tacrolimus 145-150 mechanistic target of rapamycin kinase Homo sapiens 84-88